Seqirus opens U.K. office; Mitsubishi Tanabe plans U.S. flu vaccine;

> CSL's flu vaccine unit Seqirus opened a U.K. corporate office. Release

> Japan's Mitsubishi Tanabe Pharma plans to focus on increasing its U.S. sales, with one component of its strategy involving a flu vaccine currently under development. Report

> A paper in PLOS Medicine argues in favor of a compensation system for vaccine injuries for cases such as the Ebola outbreak in which vaccines must be tested rapidly without hesitation due to liability. More

Suggested Articles

Daiichi Sankyo says it still unable to fulfill a government mandate to be able to produce enough H5N1 flu vaccine to fight an epidemic in Japan.

GSK’s Shingrix has continuously impressed industry watchers with its growth, and the company just added another large market to its list: China.

WuXi Biologics says it will build a dedicated facility to manufacture a commercial vaccine product for a client in a $3 billion contract.